EBS up +6.49% percent right now. $EBS High is at 24.46 and the Low 23.32 with current volume of 558,700.
Recent News posted below.
EBS Emergent Biosolutions Recent Headline News
Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 23.95 (+1.46)
Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 23.95 (+1.46)
Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included:
EBS: 23.95 (+1.46)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 23.95 (+1.46), NLNK: 32.15 (-2.54), TEVA: 57.70 (-1.02), AMRI: 16.84 (+0.75)
Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)
Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), EXAS: 22.82 (-0.52), AFFX: 9.43 (-0.02)
Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)
Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Mon Oct 20, 6:08AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 23.95 (+1.46)
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)
Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Infinity Pharmaceuticals (INFI) announced disappointing results from a phase IIa study on duvelisib.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), INFI: 13.01 (+0.87), ABBV: 61.50 (-1.21)
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:30PM CDT
Health Canada issued a notice of compliance to Gilead's (GILD) Harvoni.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), ENZ: 4.94 (-0.13), EPZM: 23.75 (+0.19)
Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:30PM CDT
Alexion (ALXN) has filed a new drug application for asfotase alfa in Japan.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), LGND: 53.94 (-0.97)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), AGIO: 72.06 (-11.03), CELG: 106.45 (-0.69)
GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:48PM CDT
GW Pharmaceuticals (GWPH) announced disappointing results from a phase IIa study on GWP42003.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GWPH: 73.97 (-0.41), LGND: 53.94 (-0.97)
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), NVAX: 4.95 (-0.20)
Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 3:30PM CDT
Alnylam Pharmaceuticals (ALNY) announced several study results on its pipeline candidates.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)
Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:45PM CDT
Alnylam (ALNY) revealed encouraging initial results from an ongoing phase II study on patisiran.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), PLX: 2.04 (-0.01), EPZM: 23.75 (+0.19)
Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), FCSC: 2.73 (+0.06), EPZM: 23.75 (+0.19)
Recent News posted below.
EBS Emergent Biosolutions Recent Headline News
Emergent Biosolutions posts 3Q profit
Automated Insights - Fri Nov 07, 4:04AM CST
ROCKVILLE, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Friday reported earnings of $21.8 million in its third quarter.
EBS: 23.95 (+1.46)
Emergent BioSolutions Inc Busts Through Guidance. Sort of.
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 7:39PM CST
Considering that Emergent BioSolutions has regular government contracts and other manufacturing contracts -- so regular that it's willing to give quarterly guidance, which many companies wouldn't dream of -- it was a little surprising to see by...
EBS: 23.95 (+1.46)
Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2014. Financial highlights included:
EBS: 23.95 (+1.46)
3 Biotech Stocks With Humongous Short Interest
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 22, 8:05AM CDT
Buying when everyone else is scared may sound like a fantastic way to buy great companies at bargain-basement prices, but it can be tricky to figure out when there's enough fear to justify buying, especially in hit-and-miss industries...
EBS: 23.95 (+1.46), NLNK: 32.15 (-2.54), TEVA: 57.70 (-1.02), AMRI: 16.84 (+0.75)
Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), SNY: 45.69 (-0.17), FOLD: 5.72 (-0.16)
Affymetrix-Ariosa Ink Supply Deal for Harmony Prenatal Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 3:55PM CDT
Affymetrix Inc. (AFFX) announced that it has entered a multi-year supply agreement with San Jose, California-based Ariosa Diagnostics, Inc.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), EXAS: 22.82 (-0.52), AFFX: 9.43 (-0.02)
Emergent BioSolutions (EBS) Jumps: Stock Moves Up 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 7:51AM CDT
Emergent BioSolutions, Inc. (EBS) was a big mover last session, as its shares rose nearly 6% on the day.
MACK: 8.70 (-0.07), HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), EXAS: 22.82 (-0.52)
Emergent BioSolutions to Webcast Presentation at Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Mon Oct 20, 6:08AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under "Investors."
EBS: 23.95 (+1.46)
Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Ultragenyx Pharmaceutical Inc. (RARE) reported interim data from a phase II extension study on sialic acid extended-release tablets.
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), RARE: 44.71 (-0.15), LGND: 53.94 (-0.97)
Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:00PM CDT
Infinity Pharmaceuticals (INFI) announced disappointing results from a phase IIa study on duvelisib.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), INFI: 13.01 (+0.87), ABBV: 61.50 (-1.21)
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:30PM CDT
Health Canada issued a notice of compliance to Gilead's (GILD) Harvoni.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21)
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:57AM CDT
Enzo Biochem stock could bring additional losses for your portfolio
HALO: 9.12 (-0.03), EBS: 23.95 (+1.46), ENZ: 4.94 (-0.13), EPZM: 23.75 (+0.19)
Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:30PM CDT
Alexion (ALXN) has filed a new drug application for asfotase alfa in Japan.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALXN: 193.81 (+0.67), LGND: 53.94 (-0.97)
Agios (AGIO) Rises on Expansion of Phase I Study on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:10PM CDT
Agios Pharmaceuticals (AGIO) initiated four expansion cohorts in its ongoing phase I study on AG-221.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), AGIO: 72.06 (-11.03), CELG: 106.45 (-0.69)
GW Pharmaceuticals Down on Disappointing Mid-Stage Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:48PM CDT
GW Pharmaceuticals (GWPH) announced disappointing results from a phase IIa study on GWP42003.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GWPH: 73.97 (-0.41), LGND: 53.94 (-0.97)
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), GILD: 106.45 (-0.49), NVAX: 4.95 (-0.20)
Alnylam Reveals Positive Data from its Pipeline Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 3:30PM CDT
Alnylam Pharmaceuticals (ALNY) announced several study results on its pipeline candidates.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)
Alnylam Jumps on Positive Patisiran Data from Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:45PM CDT
Alnylam (ALNY) revealed encouraging initial results from an ongoing phase II study on patisiran.
MDVN: 112.77 (+7.82), EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), LGND: 53.94 (-0.97)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 23.95 (+1.46), FCSC: 2.73 (+0.06), PLX: 2.04 (-0.01), EPZM: 23.75 (+0.19)
Alnylam Pharmaceuticals (ALNY) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:04AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) was a big mover last session, as the company saw its shares rise almost 19% on the day.
EBS: 23.95 (+1.46), ALNY: 95.84 (+2.93), FCSC: 2.73 (+0.06), EPZM: 23.75 (+0.19)
